* Prophase Labs Inc reported a quarterly adjusted loss of 35 cents per share for the quarter , lower than the same quarter last year, when the company reported EPS of -30 cents. The lone analyst forecast for the quarter was for earnings of 4 cents per share.
* Revenue fell 62.4% to $3.15 million from a year ago; analysts expected $23.85 million.
* Prophase Labs Inc's reported EPS for the quarter was a loss of 35 cents.
* Prophase Labs Inc shares had fallen by 69.5% this quarter and lost 83.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 123.5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the healthcare facilities & services peer group is also "buy"
Wall Street's median 12-month price target for Prophase Labs Inc is 18.50 This summary was machine generated from LSEG data November 13 at 03:23 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.04 -0.35 Missed
Jun. 30 2024 -0.24 -0.33 Missed
Mar. 31 2024 -0.28 -0.07 Beat
Dec. 31 2023 -0.26 -0.51 Missed
Comments